By Stephen Fink and Anupam Jena ( July 17, 2020, 6:11 PM EDT) -- In January, the state of California enacted its new legislation, A.B. 824, making reverse payment patent settlements associated with Hatch-Waxman Act pharmaceutical litigation — or pay-for-delay settlements — presumptively anti-competitive.[1]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.